Astrazeneca plc(AZN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:58 PM ET (Korea 9/12 08:58)
Full metrics table
| Index | - | P/E | 23.94 | EPS (ttm) | 6.69 | Insider Own | 3.43% | Shs Outstand | 1.55B | Perf Week | -2.79% |
| Market Cap | 248.41B | Forward P/E | 13.94 | EPS next Y | 12.07% | Insider Trans | -0.02% | Shs Float | 1.50B | Perf Month | 1.05% |
| Enterprise Value | 275.75B | PEG | 1.19 | EPS next Q | 2.62 | Inst Own | 61.12% | Short Float | 0.19% | Perf Quarter | -12.13% |
| Income | 10.45B | P/S | 4.05 | EPS this Y | 11.89% | Inst Trans | -0.96% | Short Ratio | 0.9 | Perf Half Y | -16.79% |
| Sales | 61.37B | P/B | 4.94 | EPS next 5Y | 11.76% | ROA | 9.15% | Short Interest | 2.90M | Perf YTD | -8.74% |
| Book/sh | 32.43 | P/C | 50 | EPS past 3/5Y | 45.9% 22.05% | ROE | 21.99% | 52W High | -24.7% ($212.71) | Perf Year | -1.13% |
| Cash/sh | 3.2 | P/FCF | 22.85 | Sales past 3/5Y | 9.82% 16.31% | ROIC | 13.69% | 52W Low | 9.63% ($146.10) | Perf 3Y | 18.03% |
| Dividend Est. | $3.34 (2.08%) | EV/EBITDA | 13.73 | EPS Y/Y TTM | 25.9% | Gross Margin | 73.93% | Volatility(W/M) | 2.03% 1.7% | Perf 5Y | 41.74% |
| Dividend TTM | 3.23 | EV/Sales | 4.49 | Sales Y/Y TTM | 8.61% | Oper. Margin | 22.38% | ATR (14) | 3.66 | Perf 10Y | 153.23% |
| Dividend Ex-Date | 2026/8/7 | Quick Ratio | 0.67 | EPS Q/Q | 2.26% | Profit Margin | 17.02% | RSI (14) | 44.33 | Recom | 1.2 |
| Dividend Gr. 3/5Y | 1.78% 3.25% | Current Ratio | 0.89 | Sales Q/Q | 6.41% | SMA20 | -1.41% ($162.46) | Beta | 0.33 | Target Price | $221.17 |
| Payout | 47.19% | Debt/Eq | 0.64 | Earnings | 2026/7/27 | SMA50 | -3.96% ($166.77) | Rel Volume | 0.68 | Prev Close | $159.64 |
| Employees | 96100 | LT Debt/Eq | 0.52 | EPS/Sales Surpr. | 5.98% -0.32% | SMA200 | -12.58% ($183.22) | Avg Volume(3M) | 3.21M | Price | $160.17 |
| IPO | 2003/10/17 | Option/Short | Yes/Yes | Trades | 22368 | Volume | 2,169,716 | Change | 0.33% |
Company
AZN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 A multinational pharmaceutical company operating a global novel-drug pipeline spanning oncology, cardiovascular, respiratory, and rare-disease therapeutics. It was formed through the 1999 merger of Sweden's Astra and the UK's Zeneca, is headquartered in the UK, and trades on US exchanges through American Depositary Receipts (ADRs).
Over the past 1 year, on the lower side
25% below its 1-year high.
AZN makes money exceptionally well
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +11.9% this year.
Tap to view numbers
The price looks about right
Trading at 23.9 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +18.0% if bought 5 years ago.
Tap to view numbers
The dividend is on the small side
Pays 2.08% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 61.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
EWU 0.09%
MEDX 0.05%
GDOC 0.05%
PRVS 0.05%
MJ 0.05%It ranks #4 in the industry
Based on market cap of $248B.
AZN $248B PER 23.9
LLY $1.1T PER 37.9
JNJ $640B PER 30.8
ABBV $454B PER 72.7
FAQ
What kind of company is AZN?
AZN belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of AZN?
The market cap of AZN is approximately $248.4B, ranking 59 within its sector.
Does AZN pay dividends?
AZN has a dividend yield of approximately 2.08%, with an annual dividend of $3.34.
What is the P/E ratio of AZN?
AZN has a P/E ratio of approximately 23.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for AZN?
AZN has recorded a 52-week high of $212.71 and a low of $146.10.
